Cocaine and amphetamine regulated transcript

Last updated

CART prepropeptide
Identifiers
SymbolCARTPT
NCBI gene 9607
HGNC 24323
OMIM 602606
RefSeq NM_004291
UniProt Q16568
Other data
Locus Chr. 5 q13.2
Search for
Structures Swiss-model
Domains InterPro
CART
PDB 1hy9 EBI.jpg
cocaine- and amphetamine-regulated transcript
Identifiers
SymbolCART
Pfam PF06373
InterPro IPR009106
SCOP2 1hy9 / SCOPe / SUPFAM
Available protein structures:
Pfam   structures / ECOD  
PDB RCSB PDB; PDBe; PDBj
PDBsum structure summary

Cocaine- and amphetamine-regulated transcript, also known as CART, is a neuropeptide protein that in humans is encoded by the CARTPT gene. [1] [2] CART appears to have roles in reward, feeding, and stress, [3] and it has the functional properties of an endogenous psychostimulant. [4]

Contents

Function

CART is a neuropeptide that produces similar behavior in animals as cocaine and amphetamine, but conversely blocks the effects of cocaine when they are co-administered. The peptide is found in several areas, among them the ventral tegmental area (VTA) of the brain. When CART was injected into rat VTA, increased locomotor activity was seen, which is one of the signs of "central stimulation" caused by psychostimulants, such as cocaine and amphetamine. [5] The same rats also tended to return to the place where they were injected. This is called conditioned place preference and is also seen after injection of cocaine.

CART peptides, in particular, CART(55–102), seem to have an important function in the regulation of energy homeostasis and interact with several hypothalamic appetite circuits. CART expression is regulated by several peripheral peptide hormones involved in appetite regulation, including leptin, [6] cholecystokinin and ghrelin, [7] with CART and cholecystokinin having synergistic effects on appetite regulation. [8]

CART is released in response to repeated dopamine release in the nucleus accumbens, and may regulate the activity of neurons in this area. [9] CART production is upregulated by CREB, [10] a protein thought to be involved with the development of drug addiction, and CART may be an important therapeutic target in the treatment of stimulant abuse. [11] [12] [13]

Tissue distribution

CART is an anorectic peptide and is widely expressed in both the central and peripheral nervous systems, particularly concentrated in the hypothalamus. [14] CART is also expressed outside of the nervous system in pituitary endocrine cells, adrenomedullary cells, islet somatostatin cells, and in rat antral gastrin cells. [15] Other structures and pathways associated with CART expression include the mesolimbic pathway (linking the ventral tegmental area to the nucleus accumbens) and amygdala.

CART is also found in a subset of retinal ganglion cells (RGCs), the primary afferent neurons in the retina. Specifically, it labels ON/OFF Direction Selective Ganglion Cells (ooDSGCs), a subpopulation of RGCs that stratify in both the ON and OFF sublamina of the Inner Plexiform Layer (IPL) of the retina. It is also found in a subset of amacrine cells in the Inner Nuclear Layer. [16] No role as of yet has been proposed for the location of this protein in these cell types.

Clinical significance

Studies of CART(54–102) action in rat lateral ventricle and amygdala suggest that CART plays a role in anxiety-like behavior, induced by ethanol withdrawal in rats. [17] Studies on CART knock-out mice indicates that CART modulates the locomotor, conditioned place preference and cocaine self-administration effects of psychostimulants. This suggests a positive neuromodulatory action of CART on the effects of psychostimulants in rats. [18] CART is altered in the ventral tegmental area of cocaine overdose victims, and a mutation in the CART gene is associated with alcoholism. [19] By inhibiting the rewarding effects of cocaine, CART has a potential use in treating cocaine addiction. [20]

CART peptides are inhibitors of food intake (anorectic) and closely associated with leptin and neuropeptide Y, two important food intake regulators. CART hypoactivity in the hypothalamus of depressed animals is associated with hyperphagia and weight gain. [21] [22] CART is thought to play a key role in the opioid mesolimbic dopamine circuit that modulates natural reward processes. [23] CART also appears to play an important role in higher brain functions like cognition. [24]

History

CART was found by examining changes in the brain following cocaine or amphetamine administration. CART mRNA increased with cocaine administration. One of the goals was to find an endogenous anoretic substance. CART inhibited rat food intake by as much as 30 percent. When naturally occurring CART peptides were blocked by means of injecting antibodies for CART, feeding was increased. This led to suggestions that CART may play a role – though not being the only peptide – in satiety. In the late 1980s, researchers started to synthesize structurally cocaine-like and functionally CART-like substances in order to find medications that could help treat eating disorders as well as cocaine abuse. Chemically, these substances belong to phenyltropanes. [25]

CART receptor

The putative receptor target for CART evaded identification through 2011, [26] however in vitro studies strongly suggested that CART binds to a specific G protein-coupled receptor coupled to Gi/Go, resulting in increased ERK release inside the cell. [26] [27] [28] [29] In 2020, CART was identified as the ligand for GPR160. [30] This finding was later challenged by the finding that GPR160 does not show specific binding to a radiolabeled version of CART either in a human cancer cell line that endogeneously expresses GPR160, or in a cell line that was transfected with PGR160. [31] Furthermore, CART does not induce GPR160 mediated signaling in human cells. [32]

Several fragments of CART have been tested to try and uncover the pharmacophore, [33] [34] but the natural splicing products CART(55–102) and CART(62–102) are still of highest activity, with the reduced activity of smaller fragments thought to indicate that a compact structure retaining all three of CART's disulphide bonds is preferred. [35]

See also

Related Research Articles

<span class="mw-page-title-main">Amphetamine</span> Central nervous system stimulant

Amphetamine is a central nervous system (CNS) stimulant that is used in the treatment of attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity; it is also used to treat binge eating disorder in the form of its inactive prodrug lisdexamfetamine. Amphetamine was discovered as a chemical in 1887 by Lazăr Edeleanu, and then as a drug in the late 1920s. It exists as two enantiomers: levoamphetamine and dextroamphetamine. Amphetamine properly refers to a specific chemical, the racemic free base, which is equal parts of the two enantiomers in their pure amine forms. The term is frequently used informally to refer to any combination of the enantiomers, or to either of them alone. Historically, it has been used to treat nasal congestion and depression. Amphetamine is also used as an athletic performance enhancer and cognitive enhancer, and recreationally as an aphrodisiac and euphoriant. It is a prescription drug in many countries, and unauthorized possession and distribution of amphetamine are often tightly controlled due to the significant health risks associated with recreational use.

<span class="mw-page-title-main">Orexin</span> Neuropeptide that regulates arousal, wakefulness, and appetite.

Orexin, also known as hypocretin, is a neuropeptide that regulates arousal, wakefulness, and appetite. It exists in the forms of orexin-A and orexin-B. The most common form of narcolepsy, type 1, in which the individual experiences brief losses of muscle tone, is caused by a lack of orexin in the brain due to destruction of the cells that produce it.

<span class="mw-page-title-main">Monoamine transporter</span> Proteins that function as integral plasma-membrane transporters

Monoamine transporters (MATs) are proteins that function as integral plasma-membrane transporters to regulate concentrations of extracellular monoamine neurotransmitters. The three major classes are serotonin transporters (SERTs), dopamine transporters (DATs), and norepinephrine transporters (NETs) and are responsible for the reuptake of their associated amine neurotransmitters. MATs are located just outside the synaptic cleft (peri-synaptically), transporting monoamine transmitter overflow from the synaptic cleft back to the cytoplasm of the pre-synaptic neuron. MAT regulation generally occurs through protein phosphorylation and post-translational modification. Due to their significance in neuronal signaling, MATs are commonly associated with drugs used to treat mental disorders as well as recreational drugs. Compounds targeting MATs range from medications such as the wide variety of tricyclic antidepressants, selective serotonin reuptake inhibitors such as fluoxetine (Prozac) to stimulant medications such as methylphenidate (Ritalin) and amphetamine in its many forms and derivatives methamphetamine (Desoxyn) and lisdexamfetamine (Vyvanse). Furthermore, drugs such as MDMA and natural alkaloids such as cocaine exert their effects in part by their interaction with MATs, by blocking the transporters from mopping up dopamine, serotonin, and other neurotransmitters from the synapse.

<span class="mw-page-title-main">Cholecystokinin</span> Hormone of the gastrointestinal system

Cholecystokinin is a peptide hormone of the gastrointestinal system responsible for stimulating the digestion of fat and protein. Cholecystokinin, formerly called pancreozymin, is synthesized and secreted by enteroendocrine cells in the duodenum, the first segment of the small intestine. Its presence causes the release of digestive enzymes and bile from the pancreas and gallbladder, respectively..

<span class="mw-page-title-main">Dopamine receptor</span> Class of G protein-coupled receptors

Dopamine receptors are a class of G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS). Dopamine receptors activate different effectors through not only G-protein coupling, but also signaling through different protein interactions. The neurotransmitter dopamine is the primary endogenous ligand for dopamine receptors.

<span class="mw-page-title-main">Arcuate nucleus (hypothalamus)</span>

The arcuate nucleus of the hypothalamus (ARH), or ARC, is also known as the infundibular nucleus to distinguish it from the arcuate nucleus of the medulla oblongata in the brainstem. The arcuate nucleus is an aggregation of neurons in the mediobasal hypothalamus, adjacent to the third ventricle and the median eminence. The arcuate nucleus includes several important and diverse populations of neurons that help mediate different neuroendocrine and physiological functions, including neuroendocrine neurons, centrally projecting neurons, and astrocytes. The populations of neurons found in the arcuate nucleus are based on the hormones they secrete or interact with and are responsible for hypothalamic function, such as regulating hormones released from the pituitary gland or secreting their own hormones. Neurons in this region are also responsible for integrating information and providing inputs to other nuclei in the hypothalamus or inputs to areas outside this region of the brain. These neurons, generated from the ventral part of the periventricular epithelium during embryonic development, locate dorsally in the hypothalamus, becoming part of the ventromedial hypothalamic region. The function of the arcuate nucleus relies on its diversity of neurons, but its central role is involved in homeostasis. The arcuate nucleus provides many physiological roles involved in feeding, metabolism, fertility, and cardiovascular regulation.

<span class="mw-page-title-main">Neuropeptide</span> Peptides released by neurons as intercellular messengers

Neuropeptides are chemical messengers made up of small chains of amino acids that are synthesized and released by neurons. Neuropeptides typically bind to G protein-coupled receptors (GPCRs) to modulate neural activity and other tissues like the gut, muscles, and heart.

<span class="mw-page-title-main">Neuropeptide Y</span> Mammalian protein found in Homo sapiens

Neuropeptide Y (NPY) is a 36 amino-acid neuropeptide that is involved in various physiological and homeostatic processes in both the central and peripheral nervous systems. It is secreted alongside other neurotransmitters such as GABA and glutamate. 

<span class="mw-page-title-main">Dopamine transporter</span> Mammalian protein found in Homo sapiens

The dopamine transporter is a membrane-spanning protein coded for in humans by the SLC6A3 gene, that pumps the neurotransmitter dopamine out of the synaptic cleft back into cytosol. In the cytosol, other transporters sequester the dopamine into vesicles for storage and later release. Dopamine reuptake via DAT provides the primary mechanism through which dopamine is cleared from synapses, although there may be an exception in the prefrontal cortex, where evidence points to a possibly larger role of the norepinephrine transporter.

<span class="mw-page-title-main">Agouti-related peptide</span> Mammalian protein found in Homo sapiens

Agouti-related protein (AgRP), also called agouti-related peptide, is a neuropeptide produced in the brain by the AgRP/NPY neuron. It is synthesized in neuropeptide Y (NPY)-containing cell bodies located in the ventromedial part of the arcuate nucleus in the hypothalamus. AgRP is co-expressed with NPY and acts to increase appetite and decrease metabolism and energy expenditure. It is one of the most potent and long-lasting of appetite stimulators. In humans, the agouti-related peptide is encoded by the AGRP gene.

<span class="mw-page-title-main">Neuromodulation</span> Regulation of neurons by neurotransmitters

Neuromodulation is the physiological process by which a given neuron uses one or more chemicals to regulate diverse populations of neurons. Neuromodulators typically bind to metabotropic, G-protein coupled receptors (GPCRs) to initiate a second messenger signaling cascade that induces a broad, long-lasting signal. This modulation can last for hundreds of milliseconds to several minutes. Some of the effects of neuromodulators include altering intrinsic firing activity, increasing or decreasing voltage-dependent currents, altering synaptic efficacy, increasing bursting activity and reconfiguring synaptic connectivity.

<span class="mw-page-title-main">Calcitonin gene-related peptide</span> Peptide hormone in animals

Calcitonin gene-related peptide (CGRP) is a member of the calcitonin family of peptides consisting of calcitonin, amylin, adrenomedullin, adrenomedullin 2 (intermedin) and calcitonin‑receptor‑stimulating peptide. Calcitonin is mainly produced by thyroid C cells whilst CGRP is secreted and stored in the nervous system. This peptide, in humans, exists in two forms: CGRP alpha, and CGRP beta. α-CGRP is a 37-amino acid neuropeptide and is formed by alternative splicing of the calcitonin/CGRP gene located on chromosome 11. β-CGRP is less studied. In humans, β-CGRP differs from α-CGRP by three amino acids and is encoded in a separate, nearby gene. The CGRP family includes calcitonin (CT), adrenomedullin (AM), and amylin (AMY).

<span class="mw-page-title-main">DNQX</span> Chemical compound

DNQX (6,7-dinitroquinoxaline-2,3-dione) is a competitive antagonist at AMPA and kainate receptors, two ionotropic glutamate receptor (iGluR) subfamilies. It is used in a variety of molecular biology subfields, notably neurophysiology, to assist researchers in determining the properties of various types of ion channels and their potential applications in medicine.

The neuropeptide FF receptors are members of the G-protein coupled receptor superfamily of integral membrane proteins which bind the pain modulatory neuropeptides AF and FF. The Neuropeptide FF receptor family is a member of the G protein-coupled receptor superfamily containing two subtypes, NPFF1 and NPFF2, which exhibit a high affinity for Neuropeptide FF (NPFF) peptides. NPFF1 is broadly distributed in the central nervous system with the highest levels found in the limbic system and the hypothalamus. NPFF2 is present in high density, particularly in mammals in the superficial layers of the spinal cord where it is involved in nociception and modulation of opioid functions. These receptors participate to the modulation of opioid receptor function in the brain and spinal cord, and can either reduce or increase opioid receptor function depending which tissue they are released in, reflecting a complex role for neuropeptide FF in pain responses.

<span class="mw-page-title-main">Cholecystokinin B receptor</span> Protein-coding gene in the species Homo sapiens

The cholecystokinin B receptor also known as CCKBR or CCK2 is a protein that in humans is encoded by the CCKBR gene.

<span class="mw-page-title-main">Neuropeptide Y receptor Y2</span> Protein-coding gene in the species Homo sapiens

Neuropeptide Y receptor type 2 (Y2R) is a member of the neuropeptide Y receptor family of G-protein coupled receptors, that in humans is encoded by the NPY2R gene.

<span class="mw-page-title-main">GPR160</span> Protein-coding gene in the species Homo sapiens

Probable G-protein coupled receptor 160 is a protein that in humans is encoded by the GPR160 gene. It has been identified as the receptor for Cocaine- and amphetamine-regulated transcript, also known as CART.

<span class="mw-page-title-main">Pancreatic polypeptide receptor 1</span> Protein-coding gene in the species Homo sapiens

Pancreatic polypeptide receptor 1, also known as Neuropeptide Y receptor type 4, is a protein that in humans is encoded by the PPYR1 gene.

<span class="mw-page-title-main">Monoamine releasing agent</span> Class of compounds

A monoamine releasing agent (MRA), or simply monoamine releaser, is a drug that induces the release of a monoamine neurotransmitter from the presynaptic neuron into the synapse, leading to an increase in the extracellular concentrations of the neurotransmitter. Many drugs induce their effects in the body and/or brain via the release of monoamine neurotransmitters, e.g., trace amines, many substituted amphetamines, and related compounds.

<span class="mw-page-title-main">Neuropeptide S</span> Protein-coding gene in the species Homo sapiens

Neuropeptide S (NPS) is a neuropeptide found in human and mammalian brain, mainly produced by neurons in the amygdala and between Barrington's nucleus and the locus coeruleus, although NPS-responsive neurons extend projections into many other brain areas. NPS binds specifically to a G protein-coupled receptor, NPSR. Animal studies show that NPS suppresses anxiety and appetite, induces wakefulness and hyperactivity, including hyper-sexuality, and plays a significant role in the extinction of conditioned fear. It has also been shown to significantly enhance dopamine activity in the mesolimbic pathway, and inhibits motility and increases permeability in neurocrine fashion acting through NO in the myenteric plexus in rats and humans.

References

  1. ↑ Douglass J, Daoud S (March 1996). "Characterization of the human cDNA and genomic DNA encoding CART: a cocaine- and amphetamine-regulated transcript". Gene. 169 (2): 241–5. doi:10.1016/0378-1119(96)88651-3. PMID   8647455.
  2. ↑ Kristensen P, Judge ME, Thim L, Ribel U, Christjansen KN, Wulff BS, et al. (May 1998). "Hypothalamic CART is a new anorectic peptide regulated by leptin". Nature. 393 (6680): 72–6. Bibcode:1998Natur.393...72K. doi:10.1038/29993. PMID   9590691. S2CID   4427258.
  3. ↑ Zhang M, Han L, Xu Y (November 2011). "Roles of cocaine- and amphetamine-regulated transcript in the central nervous system". Clin. Exp. Pharmacol. Physiol. 39 (6): 586–92. doi:10.1111/j.1440-1681.2011.05642.x. PMID   22077697. S2CID   25134612.
  4. ↑ Kuhar MJ, Adams S, Dominguez G, Jaworski J, Balkan B (February 2002). "CART peptides". Neuropeptides. 36 (1): 1–8. doi:10.1054/npep.2002.0887. PMID   12147208. S2CID   7079530.
  5. ↑ Kimmel HL, Gong W, Vechia SD, Hunter RG, Kuhar MJ (August 2000). "Intra-ventral tegmental area injection of rat cocaine and amphetamine-regulated transcript peptide 55-102 induces locomotor activity and promotes conditioned place preference". The Journal of Pharmacology and Experimental Therapeutics. 294 (2): 784–92. PMID   10900261.
  6. ↑ Murphy KG (July 2005). "Dissecting the role of cocaine- and amphetamine-regulated transcript (CART) in the control of appetite". Brief Funct Genomic Proteomic. 4 (2): 95–111. doi: 10.1093/bfgp/4.2.95 . PMID   16102267.
  7. ↑ de Lartigue G, Dimaline R, Varro A, Dockray GJ (March 2007). "Cocaine- and amphetamine-regulated transcript: stimulation of expression in rat vagal afferent neurons by cholecystokinin and suppression by ghrelin". Journal of Neuroscience. 27 (11): 2876–82. doi: 10.1523/JNEUROSCI.5508-06.2007 . PMC   6672594 . PMID   17360909.
  8. ↑ Maletínská L, Maixnerová J, Matysková R, Haugvicová R, Pirník Z, Kiss A, et al. (2008). "Synergistic effect of CART (cocaine- and amphetamine-regulated transcript) peptide and cholecystokinin on food intake regulation in lean mice". BMC Neuroscience. 9: 101. doi: 10.1186/1471-2202-9-101 . PMC   2587474 . PMID   18939974.
  9. ↑ Hubert GW, Jones DC, Moffett MC, Rogge G, Kuhar MJ (January 2008). "CART peptides as modulators of dopamine and psychostimulants and interactions with the mesolimbic dopaminergic system". Biochemical Pharmacology . 75 (1): 57–62. doi:10.1016/j.bcp.2007.07.028. PMC   3804336 . PMID   17854774.
  10. ↑ Rogge GA, Jones DC, Green T, Nestler E, Kuhar MJ (January 2009). "Regulation of CART peptide expression by CREB in the rat nucleus accumbens in vivo". Brain Research. 1251: 42–52. doi:10.1016/j.brainres.2008.11.011. PMC   2734444 . PMID   19046951.
  11. ↑ Fagergren P, Hurd Y (September 2007). "CART mRNA expression in rat monkey and human brain: relevance to cocaine abuse". Physiology & Behavior. 92 (1–2): 218–25. doi:10.1016/j.physbeh.2007.05.027. PMID   17631364. S2CID   11245593.
  12. ↑ Vicentic A, Jones DC (February 2007). "The CART (cocaine- and amphetamine-regulated transcript) system in appetite and drug addiction". The Journal of Pharmacology and Experimental Therapeutics. 320 (2): 499–506. doi:10.1124/jpet.105.091512. PMID   16840648. S2CID   14212763.
  13. ↑ Rogge G, Jones D, Hubert GW, Lin Y, Kuhar MJ (October 2008). "CART peptides: regulators of body weight, reward and other functions". Nature Reviews. Neuroscience. 9 (10): 747–58. doi:10.1038/nrn2493. PMC   4418456 . PMID   18802445.
  14. ↑ Keller PA, Compan V, Bockaert J, Giacobino JP, Charnay Y, Bouras C, et al. (June 2006). "Characterization and localization of cocaine- and amphetamine-regulated transcript (CART) binding sites". Peptides. 27 (6): 1328–34. doi:10.1016/j.peptides.2005.10.016. PMID   16309793. S2CID   27440114.
  15. ↑ Wierup N, Kuhar M, Nilsson BO, Mulder H, Ekblad E, Sundler F (February 2004). "Cocaine- and amphetamine-regulated transcript (CART) is expressed in several islet cell types during rat development". J. Histochem. Cytochem. 52 (2): 169–77. doi: 10.1177/002215540405200204 . PMID   14729868.
  16. ↑ Kay JN, De la Huerta I, Kim IJ, Zhang Y, Yamagata M, Chu MW, et al. (May 2011). "Retinal ganglion cells with distinct directional preferences differ in molecular identity, structure, and central projections". The Journal of Neuroscience. 31 (21): 7753–62. doi:10.1523/JNEUROSCI.0907-11.2011. PMC   3108146 . PMID   21613488.
  17. ↑ Dandekar MP, Singru PS, Kokare DM, Lechan RM, Thim L, Clausen JT, et al. (April 2008). "Importance of cocaine- and amphetamine-regulated transcript peptide in the central nucleus of amygdala in anxiogenic responses induced by ethanol withdrawal". Neuropsychopharmacology. 33 (5): 1127–36. doi: 10.1038/sj.npp.1301516 . PMID   17637604.
  18. ↑ Couceyro PR, Evans C, McKinzie A, Mitchell D, Dube M, Hagshenas L, et al. (December 2005). "Cocaine- and amphetamine-regulated transcript (CART) peptides modulate the locomotor and motivational properties of psychostimulants". J. Pharmacol. Exp. Ther. 315 (3): 1091–100. doi:10.1124/jpet.105.091678. PMID   16099925. S2CID   15989891.
  19. ↑ Kuhar MJ, Jaworski JN, Hubert GW, Philpot KB, Dominguez G (2005). "Cocaine- and amphetamine-regulated transcript peptides play a role in drug abuse and are potential therapeutic targets". AAPS J. 7 (1): E259–65. doi:10.1208/aapsj070125. PMC   2751515 . PMID   16146347.
  20. ↑ Yu C, Zhou X, Fu Q, Peng Q, Oh KW, Hu Z (2017). "A New Insight into the Role of CART in Cocaine Reward: Involvement of CaMKII and Inhibitory G-Protein Coupled Receptor Signaling". Frontiers in Cellular Neuroscience . 11: 244. doi: 10.3389/fncel.2017.00244 . PMC   5559471 . PMID   28860971.
  21. ↑ Nakhate KT, Kokare DM, Singru PS, Subhedar NK (June 2011). "Central regulation of feeding behavior during social isolation of rat: evidence for the role of endogenous CART system". Int J Obes (Lond). 35 (6): 773–84. doi:10.1038/ijo.2010.231. PMID   21060312. S2CID   23362880.
  22. ↑ Dandekar MP, Singru PS, Kokare DM, Subhedar NK (April 2009). "Cocaine- and amphetamine-regulated transcript peptide plays a role in the manifestation of depression: social isolation and olfactory bulbectomy models reveal unifying principles". Neuropsychopharmacology. 34 (5): 1288–300. doi: 10.1038/npp.2008.201 . PMID   19005467.
  23. ↑ Upadhya MA, Nakhate KT, Kokare DM, Singh U, Singru PS, Subhedar NK (March 2012). "CART peptide in the nucleus accumbens shell acts downstream to dopamine and mediates the reward and reinforcement actions of morphine". Neuropharmacology. 62 (4): 1823–33. doi:10.1016/j.neuropharm.2011.12.004. PMID   22186082. S2CID   10500678.
  24. ↑ Bharne AP, Borkar CD, Bodakuntla S, Lahiri M, Subhedar NK, Kokare DM (2016). "Pro-cognitive action of CART is mediated via ERK in the hippocampus". Hippocampus. 26 (10): 1313–27. doi:10.1002/hipo.22608. PMID   27258934. S2CID   4876304.
  25. ↑ "Cocaine Studies Reveal New Medications For Addiction; How Brain Regulates Hunger". ScienceDaily LLC. 27 October 1997. Retrieved 11 February 2009.
  26. 1 2 Lin Y, Hall RA, Kuhar MJ (October 2011). "CART peptide stimulation of G protein-mediated signaling in differentiated PC12 cells: identification of PACAP 6-38 as a CART receptor antagonist". Neuropeptides. 45 (5): 351–8. doi:10.1016/j.npep.2011.07.006. PMC   3170513 . PMID   21855138.
  27. ↑ Lakatos A, Prinster S, Vicentic A, Hall RA, Kuhar MJ (2005). "Cocaine- and amphetamine-regulated transcript (CART) peptide activates the extracellular signal-regulated kinase (ERK) pathway in AtT20 cells via putative G-protein coupled receptors". Neuroscience Letters. 384 (1–2): 198–202. doi:10.1016/j.neulet.2005.04.072. PMID   15908120. S2CID   16175568.
  28. ↑ Vicentic A, Lakatos A, Kuhar MJ (December 2005). "CART (cocaine- and amphetamine-regulated transcript) peptide receptors: specific binding in AtT20 cells". European Journal of Pharmacology. 528 (1–3): 188–9. doi:10.1016/j.ejphar.2005.11.041. PMID   16330022.
  29. ↑ Maletínská L, Maixnerová J, Matysková R, Haugvicová R, Sloncová E, Elbert T, et al. (March 2007). "Cocaine- and amphetamine-regulated transcript (CART) peptide specific binding in pheochromocytoma cells PC12". European Journal of Pharmacology. 559 (2–3): 109–14. doi:10.1016/j.ejphar.2006.12.014. PMID   17292884.
  30. ↑ Yosten GL, Harada CM, Haddock C, Giancotti LA, Kolar GR, Patel R, et al. (May 2020). "GPR160 de-orphanization reveals critical roles in neuropathic pain in rodents". The Journal of Clinical Investigation. 130 (5): 2587–2592. doi:10.1172/JCI133270. PMC   7190928 . PMID   31999650.
  31. ↑ Freitas-Lima LC, Pačesová A, Staňurová J, Šácha P, Marek A, Hubálek M, et al. (June 2023). "GPR160 is not a receptor of anorexigenic cocaine- and amphetamine-regulated transcript peptide". European Journal of Pharmacology. 949: 175713. doi: 10.1016/j.ejphar.2023.175713 . PMID   37054941.
  32. ↑ Ye C, Zhou Q, Lin S, Yang W, Cai X, Mai Y, et al. (March 2024). "High expression of GPR160 in prostate cancer is unrelated to CARTp-mediated signaling pathways". Acta Pharmaceutica Sinica. B. 14 (3): 1467–1471. doi:10.1016/j.apsb.2023.11.025. PMC   10935005 . PMID   38487007.
  33. ↑ Bannon AW, Seda J, Carmouche M, Francis JM, Jarosinski MA, Douglass J (December 2001). "Multiple behavioral effects of cocaine- and amphetamine-regulated transcript (CART) peptides in mice: CART 42-89 and CART 49-89 differ in potency and activity". The Journal of Pharmacology and Experimental Therapeutics. 299 (3): 1021–6. PMID   11714891.
  34. ↑ Dylag T, Kotlinska J, Rafalski P, Pachuta A, Silberring J (August 2006). "The activity of CART peptide fragments". Peptides. 27 (8): 1926–33. doi:10.1016/j.peptides.2005.10.025. PMID   16730858. S2CID   2659119.
  35. ↑ Maixnerová J, Hlavácek J, Blokesová D, Kowalczyk W, Elbert T, Sanda M, et al. (October 2007). "Structure-activity relationship of CART (cocaine- and amphetamine-regulated transcript) peptide fragments". Peptides. 28 (10): 1945–53. doi:10.1016/j.peptides.2007.07.022. PMID   17766010. S2CID   40284900.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.